Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III Trial
Israeli-French drug development company Novagali SA, which was founded on the basis of research conducted by Prof. Simon Benita of the Hebrew University of Jerusalem, has successfully completed European Medicines Agency (EMEA) Phase III clinical trials of its eye treatment for Vernal Keratoconjunctivitis (VKC)..
This is a rare form of chronic allergic conjunctivitis seen in children and characterized by ocular discomfort, pain, itching and intense photophobia (sensitivity to light), which severely debilitates the patients.
The drug has been classified by the EMEA as an orphan drug. The company said that it would file for European Marketing Authorization by mid-2007.
Novagali has several eye treatments undergoing advanced clinical trials. Its next product will be designed to treat Dry Eye Syndrome.
Filed under Eye Treatment
You may also like to read
- Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure
- Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular Degeneration
- VEGF Trap-Eye Phase 2 trial reports significant improvement in neovascular disease
- Can-Fite Begins Phase II Trials for Treatment of Symptoms of Keratitis Sicca (Dry-Eye Syndrome)
- Chennai records rare form of eye disease
- Epidemic Keratoconjunctivitis Spreading Quickly In Korea
- Combination Antibiotic-Steroid for Ocular Inflammation Filed for FDA Approval
- India and Australia Come Together For The Clinical Trial Of Selenium-Coated Contact Lenses
- Inspire applied to FDA for Special Protocol Assessment for dry eye treatment drug
- FDA offers single medical device for treating two types of eye disease
